|
|
Annette Deichmann, Salima Hacein-Bey-Abina, Manfred Schmidt, Alexandrine Garrigue, Martijn H. Brugman, Jingqiong Hu, Hanno Glimm, Gabor Gyapay, Bernard Prum, Christopher C. Fraser, Nicolas Fischer, Kerstin Schwarzwaelder, Maria-Luise Siegler, Dick de Ridder, Karin Pike-Overzet, Steven J. Howe, Adrian J. Thrasher, Gerard Wagemaker, Ulrich Abel, Frank J.T. Staal, Eric Delabesse, Jean-Luc Villeval, Bruce Aronow, Christophe Hue, Claudia Prinz, Manuela Wissler, Chuck Klanke, Jean Weissenbach, Ian Alexander, Alain Fischer, Christof von Kalle, Marina Cavazzana-Calvo
J Clin Invest. 2007;
117(8):2225
doi:10.1172/JCI31659
Abstract |
Full text
| PDF
| Supplemental material

R
ecent reports have challenged the notion that retroviruses and retroviral vectors integrate randomly into the host genome. These reports pointed to a strong bias toward integration in and near gene coding regions and, for gammaretroviral vectors, around transcription start sites. Here, we report the results obtained from a large-scale mapping of 572 retroviral integration sites (RISs) isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol. Our data showed that two-thirds of insertions occurred in or very near to genes, of which more than half were highly expressed in CD34+ progenitor cells. Strikingly, one-fourth of all integrations were clustered as common integration sites (CISs). The highly significant incidence of CISs in circulating T cells and the nature of their locations indicate that insertion in many gene loci has an influence on cell engraftment, survival, and proliferation. Beyond the observed cases of insertional mutagenesis in 3 patients, these data help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID-X1.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(95)
| Title and authors |
Publication |
Year |
Role of the common chain in cell cycle progression of human malignant cell lines
I. Vigliano, L. Palamaro, G. Bianchino, A. Fusco, L. Vitiello, V. Grieco, R. Romano, M. Salvatore, C. Pignata
|
International Immunology
|
2012 |
Methods in Enzymology
Jennifer D. Stone, Adam S. Chervin, David H. Aggen, David M. Kranz
|
Protein Engineering for Therapeutics Part B
|
2012 |
Retroviral Integrations in Gene Therapy Trials
Luca Biasco, Cristina Baricordi, Alessandro Aiuti
|
Mol Ther
|
2012 |
Hematopoietic stem cell engineering at a crossroads
I. Riviere, C. E. Dunbar, M. Sadelain
|
Blood
|
2012 |
Methods in Enzymology
Alain Fischer, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo
|
Gene Transfer Vectors for Clinical Application
|
2012 |
Methods in Enzymology
Eugenio Montini, Daniela Cesana
|
Gene Transfer Vectors for Clinical Application
|
2012 |
Ex vivo gene transfer and correction for cell-based therapies
Luigi Naldini
|
Nat Rev Genet
|
2011 |
Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man
Rudi W Hendriks, Robbert GM Bredius, Karin Pike-Overzet, Frank JT Staal
|
Expert Opin. Ther. Targets
|
2011 |
Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell
Luca Biasco, Alessandro Ambrosi, Danilo Pellin, Cynthia Bartholomae, Immacolata Brigida, Maria Grazia Roncarolo, Clelia Di Serio, Christof von Kalle, Manfred Schmidt, Alessandro Aiuti
|
EMBO Mol Med
|
2011 |
Genotoxicity of retroviral hematopoietic stem cell gene therapy
Grant D Trobridge
|
Expert Opin. Biol. Ther.
|
2011 |
|